The course of metastatic prostate cancer under treatment

Demir A., Cecen K., Karadag M. A., Kocaaslan R., Turkeri L.

SPRINGERPLUS, cilt.3, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 3
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1186/2193-1801-3-725
  • Dergi Adı: SPRINGERPLUS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
  • Anahtar Kelimeler: Metastatic prostate cancer, Treatment modality, Course, ANDROGEN-DEPRIVATION THERAPY, CARDIOVASCULAR COMPLICATIONS, HORMONAL-THERAPY, CASTRATION, BLOCKADE, TRIAL, MEN, BICALUTAMIDE, ORCHIECTOMY, MANAGEMENT
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

The first-line management of metastatic prostate cancer is hormonal therapy. However, resistance to this treatment will emerge within an average of 24 months. Our purpose was to determine the course of metastatic prostate cancer under treatment.